CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
MIRAPEX® - low +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02231918
NCT02231918Phase 2Completed
CompareCT.gov

An Open-label Clinical Study to Investigate Pharmacokinetics (PK) of Different Doses (0.125 mg, 0.25 mg, 0.5 mg) of Pramipexole Administered Once Daily Orally in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)

Boehringer Ingelheim·interventional·Posted Sep 4, 2014·Updated Oct 6, 2015

In Brief

A Phase 2 clinical trial evaluating MIRAPEX® - low, MIRAPEX® - medium, and 1 other intervention for Restless Legs Syndrome. Completed, enrolled 26 participants.

Detailed Summary

Study to determine the pharmacokinetics (PK) of pramipexole (PPX) after administration of a single dose orally (p.o.) in pediatric patients with the diagnosis of RLS

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRestless Legs Syndrome
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 4, 2014
Enrollment StartMay 1, 2006
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.8 years ago

Interventions

MIRAPEX® - lowdrug

MIRAPEX® - mediumdrug

MIRAPEX® - highdrug